A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patient...
Ductal carcinoma in situ (DCIS) may often be overtreated in older women with limited life expectancy, according to research presented during the 2024 Society of Surgical Oncology (SSO) Annual Meeting....
Recent research has provided valuable insights into the long-term outcomes of patients with pathogenic BRCA1 and BRCA2 mutations who undergo breast-conserving therapy, according to a study presented a...
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies the ri...
Jenny H. Chang, MD, of the Cleveland Clinic, discusses the current surgical and radiologic treatment paradigm for patients with stage III Merkel cell carcinoma and the potential for neoadjuvant immuno...
Judy C. Boughey, MD, of the Mayo Clinic, discusses findings from the I-SPY2 trial, which show that although the extent of residual disease and tumor biology in patients with breast cancer may impact o...
Akhil G. Pachimatla, MD, of Roswell Park Comprehensive Cancer Center, discusses study findings showing that, in patients with non–small cell lung cancer (NSCLC), image-based adiposity measures show st...
Kerollos N. Wanis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses a study in which he evaluated the risk of future ipsilateral and contralateral breast cancer events in a lar...
Heather McArthur, MD, MPH, of UT Southwestern Medical Center, discusses phase III findings from the KEYNOTE-756 trial, which shows that adding pembrolizumab to neoadjuvant chemotherapy increases patho...
Natália Polidorio, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses findings on the impact of race on pathologic complete response in patients with early-stage triple-negative breast canc...